

Norah Anne Terrault, M.D., M.P.H.

Professor of Clinical Medicine

Director, Advanced Transplant Hepatology Fellowship Program

Director of Viral Hepatitis Research in Liver Transplantation

Academic Office and Laboratory

Division of Gastroenterology

513 Parnassus Avenue, Room S-357

San Francisco, CA 94143-0358

Phone: 415-476-2227

Fax: 415-476-0659

Email: norah.terrault@ucsf.edu



Clinic

UCSF GI Faculty Practice

350 Parnassus Avenue, Suite 410

San Francisco, CA 94143-0657

Phone: 415-353-2318

Fax: 415-353-2407

Active Projects:

- Natural history and therapies to prevention complications of cirrhosis in patients with HCV and HBV.
- Outcomes of HCV infection in dialysis patients and those undergoing kidney transplantation.
- Natural history of post liver transplantation disease in patients with HCV infection, determinants of disease severity and management strategies for recurrent disease.
- Therapeutic trials with new drugs to treat chronic HBV and HCV.

Techniques in Use:

- Population-based studies with sentinel surveillance for incident and prevalent cases.
- Cohort and case control studies for in patients with chronic HBV and HCV.
- Phase I, II, and III clinical trials.

Education

- 1985 B.MSc., University of Alberta
- 1987 M.D., University of Alberta
- 1997 M.P.H. University of California, Berkeley

Training

Internship and Residency

- 1987-88 Internship, University of Toronto
- 1988-91 Internal Medicine, University of Toronto
- 1991-93 Gastroenterology, University of Toronto

Fellowships

- 1994-95 Clinical Hepatology, Division of Gastroenterology, University of Toronto, Supervisor: S.V. Feinman
- 1995-97 Research Hepatology, Division of Gastroenterology, University

Certification

- 1991 Diplomate of the American Board of Internal Medicine
- 1992 Fellow in the Royal College of Physicians of Canada (FRCPC), Internal Medicine
- 1993 Diplomate of the American Board of Gastroenterology
- 1993 Fellow in the Royal College of Physicians of Canada (FRCPC), Gastroenterology
- 2004 Recertification, American Board of Internal Medicine

- 2004 Recertification, American Board of Gastroenterology
- 2006 Certificate of Added Qualification, Transplant Hepatology
- 1988-1999: Medical licensure, Ontario, Canada
- 1994-current: Medical licensure, California, No. A60147

Memberships and Affiliations

Memberships in Professional Associations

1994	American Association for the Study of Liver Diseases (Trainee)
1994	American Gastroenterology Association (Trainee)
1995	Canadian Association for the Study of Liver Diseases (Member)
1995	Canadian Association of Gastroenterology (Member)
1997	American Association for the Study of Liver Diseases (Member)
1999	International Liver Transplant Society (Member)
2000	American Gastroenterology Association (Member)
2003	American Society of Transplantation (Member)
2008	American College of Gastroenterology (Member)

Committee Membership/Chair Positions

1999-2001	Member, Clinical Research Committee, AASLD
2000-1	Vice-Chair, ADHF, Digestive Health Initiative, Women's GI Health
2002-2004	Member, Scientific Program Committee, AASLD
2002-2004	Chair, Clinical Research Committee, AASLD
2002-	Board member, Hepatitis Foundation International
2003-	NIDDK Liver Disease Research Branch Working Group for trans-NIH Action Plan for Liver Disease Research.
2005-2007	Member, Practice Guideline Committee, AST
2005-	Member, Program Review Committee, AASLD
2007-	Member, ABIM Transplant Hepatology Test Committee
2008	Member, Nominating Committee, AASLD

Selected Publications

- Galun E, Terrault NA, Eren R, Zauberman A, Nussbaum O, Terkieltaub D, Zohar M, Buchnik R, Ackerman Z, Safadi R, Ashur Y, Misrachi S, Liberman Y, Rivkin L, Dagan S. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. *J Hepatol.* 2007 Jan;46(1):37-44.
- Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA. Influence of cannabis use on severity of hepatitis C disease. *Clin Gastroenterol Hepatol.* 2008;6(1):69-7.
- Kuo A, Tan V, Lan B, Khalili M, Feng S, Roberts JP, Terrault NA. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. *Liver Transplant* 2008, *in press*.
- Kuo A, Terrault NA. Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters? *J Hepatol.* 2007;46(3):359-61.
- Irwin J, Terrault NA. Cognitive Impairment in hepatitis C patients on antiviral therapy. *Gastroenterol Hepatol* 2008;4:65-67
- Terrault NA, Jacobson IM. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. *Semin Liver Dis.* 2007;27 Suppl 1:18-24.
- Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. *J Viral Hepat.* 2007;14 Suppl 1:37-44.
- Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. *Clin J Am Soc Nephrol.* 2007;2(3):563-75.
- Samuel D, Weber R, Stock P, Duclos-Vallée JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? *J Hepatol.* 2008;48(5):697-707.
- Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH; VIRAHEP-C Study Group. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. *Clin Gastroenterol Hepatol.* 2008 Dec;6(12):1403-11.

- Terrault NA. Hepatitis C therapy before and after liver transplantation. *Liver Transpl*. 2008 Oct;14 Suppl 2:S58-66.
- Terrault NA, Tran TT, Schiff E, McGuire BM, Brown RS Jr, Tupper R, Ramanathan S, Enejosa J, Zhong L, Zong J; Study 531 Team. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. *Liver Int*. 2009 Sep;29(8):1178-83.
- Terrault NA. Benefits and risks of combination therapy for hepatitis B. *Hepatology*. 2009 May;49(5 Suppl):S122-8.
- Terrault NA, Pessoa, MG. Pre- and Post-Transplant Management of Hepatitis C. Textbook in *Transplant Hepatology*. Trotter J and Everson G, editors, *in press*.
- Biggins SW, Bambha K, Terrault N, Inadomi J, Roberts JP, Bass N. Transplant tourism to China: the impact on domestic patient-care decisions. *Clin Transplant*. 2009 Nov-Dec;23(6):831-8.
- Kuo A, Terrault NA. Is recurrent hepatitis C worse with living donors? *Curr Opin Organ Transplant*. 2009 Jun;14(3):240-4.
- Coffin CS, Terrault NA. Management of patients co-infected with HBV and HCV. *Expert Rev Anti Infect Ther*. 2009 Jun;7(5):549-58.
- Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, Seaberg E, Justman J, Levine AM, Mack WJ, Kovacs A. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). *AIDS Patient Care STDS*. 2009 Nov;23(11):915-23.
- Behler CM, Terrault NA, Etzell JE, Damon LE. Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. *J Med Case Reports*. 2009 Jul 6;3:7335.
- Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. *Gastroenterology*. 2009 Nov;137(5):1680-6.
- Valadao RM, Terrault NA. Older donors: mounting risks for the hepatitis C-infected liver transplant recipient? *Liver Transpl*. 2009 Jul;15(7):677-81.
- Terrault NA, Tran TT, Schiff E, McGuire BM, Brown RS Jr, Tupper R, Ramanathan S, Enejosa J, Zhong L, Zong J; Study 531 Team. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. *Liver Int*. 2009 Sep;29(8):1178-83.
- Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. *J Viral Hepat*. 2010 Jul 8.
- Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. *Inflamm Bowel Dis*. 2010 Jun;16(6):925-32.
- Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. *Curr Opin Organ Transplant*. 2010 Jun;15(3):301-9.
- Thomas DL, Di Bisceglie AM, Alter HJ, Terrault NA. Understanding the natural history of chronic HBV and HCV infections. *J Fam Pract*. 2010 Apr;59(4 Suppl):S17-22.
- Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME, Terrault NA. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfecting transplant recipients. *Am J Transplant*. 2010 May;10(5):1268-75.
- Bacchetti P, Boylan RD, Terrault NA, Monto A, Berenguer M. Non-Markov Multistate Modeling Using Time-Varying Covariates, with Application to Progression of Liver Fibrosis due to Hepatitis C Following Liver Transplant. *Int J Biostat*. 2010 Feb 20;6(1):Article7.
- Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. *J Viral Hepat*. 2011 Jun;18(6):415-23.
- Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. *Am J Transplant*. 2010 Dec;10(12):2658-64.
- Lai JC, Feng S, Roberts JP, Terrault NA. Gender differences in liver donor quality are predictive of graft loss. *Am J Transplant*. 2011 Feb;11(2):296-302.
- Trotter JF, Gillespie BW, Terrault NA, Abecassis MM, Merion RM, Brown RS Jr, Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE; Adult-to-Adult Living Donor Liver

Transplantation Cohort Study Group. Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. *Liver Transpl.* 2011;17:409-17.

- Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; PHOENIX Study Group. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. *Liver Transpl.* 2011 May;17(5):528-38.
- Brandman D, Pingitore A, Lai J, Roberts J, Ferrell L, Bass N, Terrault N. Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus. *Liver Transpl.* 2011 Jul 18.
- Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. *PLoS One.* 2011;6(5):e20104.
- Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA; Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. *Hepatology.* 2011 Aug;54(2):418-24
- Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. *Liver Transpl.* 2011 Aug;17(8):955-62.
- Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. *J Hepatol.* 2011 Sep;55(3):507-9.